Abiraterone approved for clinical use in Scotland

Posted on August 13, 2012 by Sitemaster

As previously projected, the Scottish Medicines Consortium has now approved the clinical use of abiraterone acetate, making the drug available for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after failure of treatment with docetaxel-based chemotherapy throughout the United Kingdom.

Filed under: Drugs in development, Management, Treatment | Tagged: , | Leave a comment »

Tea drinking and risk for prostate cancer (in Scotland if nowhere else)

Posted on June 25, 2012 by Sitemaster

Back in the dim and distant past (i.e., the 1960s and 1970s), relatively high levels of tea consumption were common in most of the United Kingdom, and coffee was an uncommon substitute. This is certainly not so true today. However, … READ MORE …

Filed under: Diagnosis, Risk | Tagged: , , , , | 3 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives